The first human trial designed to test the use of CRISPR-Cas for melanoma builds on the demonstrated success of previous immunotherapies, including PD-1 inhibitors89 and T cells transduced with the NY-ESO-1 T-cell receptor (TCR)90. This evidence concerns the gene PDCD1 and melanoma.